Navigation Links
Takeda and Arbor Announce a Licensing Agreement for EDARBI and EDARBYCLOR
Date:9/12/2013

DEERFIELD, Ill. and OSAKA, Japan and ATLANTA, Sept. 12, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) and Arbor Pharmaceuticals Ireland Ltd., a wholly-owned subsidiary of Arbor Pharmaceuticals, LLC ("Arbor") announced today that Takeda and Arbor have entered into a license, development and commercialization agreement. It will provide Arbor with exclusive rights to market and sell EDARBI (azilsartan medoxomil) and EDARBYCLOR (azilsartan medoxomil and chlorthalidone) in the U.S. market effective September 12, 2013.

Under the terms of the agreement, Arbor will have exclusive rights to promote and sell EDARBI and EDARBYCLOR in the United States. In return, Takeda will receive an upfront payment along with a series of future milestone and royalty payments based upon sales of the EDARBI family of products.

"This is an opportunity to capture the value that we've created in developing and launching the EDARBI family of products while positioning us to optimize our commercial resources to support our recent and anticipated launches of new products," said Douglas Cole, president, Takeda Pharmaceuticals U.S.A., Inc. "We are pleased to entrust the EDARBI family in the United States to Arbor who will continue to ensure EDARBI products are available as a treatment option to patients with hypertension. Takeda maintains its global commitment to find new therapies and expand upon the cardiovascular metabolic franchise. The EDARBI family of products remains a priority for a variety of Takeda's markets globally."

"We are excited about our acquisition of U.S. rights to EDARBI and EDARBYCLOR and look forward to representing these important brands to patients and healthcare providers," said Ed Schutter, president & CEO of
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Takedas New Investigational Drug Vedolizumab is Granted Priority Review Status by U.S. Food and Drug Administration for Ulcerative Colitis
2. Takeda EXAMINE Cardiovascular Safety Outcomes Trial of Alogliptin Met Primary Endpoint of Non-Inferiority Compared to Placebo in Addition to Standard of Care Showing No Increase in Cardiovascular Risk in Type 2 Diabetes Patients at High-Risk for Car
3. Takeda and Zinfandel Pharmaceuticals Initiate Phase 3 TOMMORROW Trial of AD-4833 for the Delay of Onset of Mild Cognitive Impairment Due to Alzheimers Disease in Subjects Selected Using a Genetic-Based Biomarker Risk Assignment Algorithm
4. Takeda Launches New Subsidiary in Peru
5. Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohns Disease
6. Among New Agents Entering the Unipolar Depression Market Over the Next Decade, Lundbeck/Takeda Pharmaceuticals Brintellix Has Blockbuster Potential
7. Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohns Disease and Ulcerative Colitis in the United States
8. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
9. AGA Research Foundation Announces Endowment Gift from Takeda Pharmaceuticals U.S.A., Inc. to Support Gastroenterology Research
10. Takeda to Acquire Inviragen, Inc.
11. Takeda Responds to Verdict in Diabetes Drug Case
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... -- Huntington Memorial Hospital is the first facility in ... replacement (TAVR), a minimally invasive replacement of heart valves. ... replace an aortic valve without a chest incision or ... The procedure is performed by a dedicated Huntington Hospital ... , MD, interventional cardiologist and Robbin Cohen , ...
(Date:3/26/2015)... S.C. , March 26, 2015 ... told by their existing PACS vendor their system ... (CMH) determined that they needed a better structured ... Hospital selected Avreo interWORKS due to its interface ... modern meaningful use standards through to the hospital,s ...
(Date:3/26/2015)... , March 26, 2015  Desert Valley Medical Center, ... times , is the first U.S. hospital to ... emergency department to help clinicians prevent hospital acquired pressure ... Victorville, Calif. , is a community hospital serving ... Using the Leaf Patient Monitor in the hospital,s emergency ...
Breaking Medicine Technology:Huntington Memorial Hospital Performs Groundbreaking Minimally Invasive Replacement of Heart Valves 2Clinch Memorial Hospital Modernizes Workflow with Avreo interWORKS 2Desert Valley Medical Center First to Use Leaf Healthcare Patient Wearable Technology in its ED as Part of Hospital-wide Deployment 2Desert Valley Medical Center First to Use Leaf Healthcare Patient Wearable Technology in its ED as Part of Hospital-wide Deployment 3
... within 5,minutes of dosing and is well-tolerated , ... Ltd,("Archimedes"), a European specialty pharmaceutical company, today,presented new ... Nasalfent(r),an innovative fentanyl citrate nasal spray aimed at ... cancer,pain. Data were presented at the 10th Congress ...
... dosed every two weeks achieved an SVR rate ... analysis), with,more favorable quality-of-life scores -, ROCKVILLE, Md., ... today announced the top-line final results of,a Phase ... with ribavirin in treatment-naive patients with,genotype 1 chronic ...
Cached Medicine Technology:Archimedes Pharma Presents Positive Efficacy and Safety Data on,Nasalfent at European Association for Palliative Care Congress 2Archimedes Pharma Presents Positive Efficacy and Safety Data on,Nasalfent at European Association for Palliative Care Congress 3Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 2Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 3Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 4Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 5Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 6Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 7Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon 8
(Date:3/26/2015)... CA (PRWEB) March 26, 2015 The American ... will be on the topics of the DAOM Program as ... DAOM Program Overview Webinar will be hosted by Dr. Carla ... provide the next steps on how to prepare for the ... p.m. March 25, March 27, April 1 and April 3. ...
(Date:3/26/2015)... Doctors Scott Sullivan and Frank DellaCroce, Co-Founders of the ... the St. Charles Surgical Hospital (SCSH) in ... Surgical Oncologist Dr. William Karl Ordoyne has joined their ... surgical oncologist Alan Stolier, M.D., FACS and the team ... Sullivan, M.D., FACS; Chris Trahan, M.D., FACS; M. Whitten ...
(Date:3/26/2015)... PA (PRWEB) March 26, 2015 The ... a new team of nationally renowned scientists to focus ... B, a move that nearly triples its research capacity ... focusing solely on hepatitis B and liver cancer in ... Timothy Block, Jinhong Chang, Ju Tao Guo and Ying-Hsiu ...
(Date:3/26/2015)... 2015 Behavioral Research Group, LLC ... the release of BathroomMap® , a new bathroom ... to public restrooms for travelers, especially those with medical ... does not facilitate a paid, social or crowdsourced model, ... rate local establishments that have clean, available restrooms in ...
(Date:3/26/2015)... Visiting Nurse Association of Northern New Jersey ... Lighting the Way, Brightening the Day, on Friday, May ... in Morristown, NJ. , Guests will enjoy an ... Clemente, delightful cuisine, an extensive silent auction and heart-warming ... prestigious awards will be presented to this year’s honorees. ...
Breaking Medicine News(10 mins):Health News:ACTCM Announces Upcoming Webinars 2Health News:Surgical Oncologist Joins Center for Restorative Breast Surgery and St. Charles Surgical Hospital 2Health News:Surgical Oncologist Joins Center for Restorative Breast Surgery and St. Charles Surgical Hospital 3Health News:Baruch S. Blumberg Institute Recruits World-Class Hepatitis B Scientists 2Health News:Baruch S. Blumberg Institute Recruits World-Class Hepatitis B Scientists 3Health News:Baruch S. Blumberg Institute Recruits World-Class Hepatitis B Scientists 4Health News:New Bathroom Finder App, BathroomMap®, Helps People with Medical Needs Who Urgently Need a Bathroom When Traveling 2Health News:New Bathroom Finder App, BathroomMap®, Helps People with Medical Needs Who Urgently Need a Bathroom When Traveling 3Health News:Morristown VNA Fundraiser to Honor Distinguished Community Members 2
... China Yingxia,International, Inc. (OTC Bulletin Board: CYXI) ... the nutraceutical industry engaged in the,development, manufacture ... and personal care products in the People,s ... has retained CCG Elite to design,and execute ...
... About the Importance of Regular Eye Care, ... the nationwide launch of its "See America" contest, ... preventive eye exams to promote,overall vision health. The ... sight will award the grand prize winner,with the ...
... Clinicogenomic Model Has Highest Prediction Accuracy for Lung ... an emerging,leader in the field of molecular diagnostics ... model for lung cancer diagnosis in the,inaugural edition ... American Association for Cancer Research (AACR), which is ...
... to expand the $200 million surgical ... Group, WALTHAM, Mass., April 14, 2008 According ... 2008 report,the surgical navigation market was worth almost $200 ... five years. This growth will be partly,facilitated by soft ...
... BioElectronics President, CEO, and Chairman Issues Shareholder ... Andrew Whelan,President, CEO and Chairman of BioElectronics, ... FDA-cleared, drug-free anti-inflammatory patch,with an embedded battery ... relieve pain and speed healing, today issued ...
... 14 The rating,agency Standard & Poor,s has raised ... stable". This means that Gerresheimer is now only one,step ... justification for the upgrade, Standard & Poor,s emphasises the,positive ... EBITDA.,Gerresheimer, it says, will be able to sustain this ...
Cached Medicine News:Health News:China Yingxia International, Inc. Retains CCG Elite 2Health News:China Yingxia International, Inc. Retains CCG Elite 3Health News:Prevent Blindness America Invites Consumers to 'See America' Through Nationwide Contest 2Health News:Prevent Blindness America Invites Consumers to 'See America' Through Nationwide Contest 3Health News:Prevent Blindness America Invites Consumers to 'See America' Through Nationwide Contest 4Health News:Allegro Diagnostics Announces Publication in Cancer Prevention Research of Prediction Model for Lung Cancer Diagnosis Integrating Clinical and Genomic Features 2Health News:Allegro Diagnostics Announces Publication in Cancer Prevention Research of Prediction Model for Lung Cancer Diagnosis Integrating Clinical and Genomic Features 3Health News:New Technology Promises Safer Organ Transplants and Soft Tissue Surgeries 2Health News:New Technology Promises Safer Organ Transplants and Soft Tissue Surgeries 3Health News:BioElectronics CEO Andrew Whelan: Positioning the Company for Growth During 2008 and Beyond 2Health News:BioElectronics CEO Andrew Whelan: Positioning the Company for Growth During 2008 and Beyond 3Health News:BioElectronics CEO Andrew Whelan: Positioning the Company for Growth During 2008 and Beyond 4Health News:Standard & Poor's Raises Gerresheimer Rating to BB+ 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: